vTv Therapeutics (VTVT) risk factors

67 risks, 6 new, 6 dropped, 10 reworded since the prior year. Expanded disclosures cover new competitive threats from approved treatments like Teplizumab and Lantidra. Details added regarding share issuances, private placements, and governance amendments involving MacAndrews. Tax receivable agreement risks updated to reflect potential excess cash payments to M&F.

67 risks. vTv Therapeutics is entirely dependent on securing additional capital to fund its operations and clinical trials. The company focuses heavily on developing its lead drug candidate, cadisegliatin (TTP399), for type 1 diabetes. Intellectual property protection and third-party dependencies like CROs and manufacturers dominate the operational risks.